|Description||MK-0359 is a selective and potent oral PDE4 inhibitor with in vivoefficacy in animal models of asthma and cognition.|
|Solubility||Soluble in DMSO|
|Storage||Store at -20 °C|
|Quality Standard||Enterprise standard|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.|
Crisaborole is a novel PDE-4 inhibitor used as a nonsteroidal topical medication for the treatment of mild-to-moderate atopic dermatitis (eczema). Crisaborole s...
MK0873 is a phosphodiesterase 4 (PDE4) inhibitor. It has shown as an innovative tool to design topical formulation to achieve desired pharmacokinetics in humans...
Roflumilast has antiinflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such ...
S-(+)-Rolipram inhibits human monocyte cyclic AMP-specific PDE4 with IC50 of 0.75 μM, has anti-inflammatory and anti-depressant activity in the central nervous ...
Rolipram is a selective PDE4-inhibitor and an anti-inflammatory agent.
Tilivapram, a pyridine derivative, has been found to be a phosphodiesterase IV inhibitor that could probably be used in studying its bioactivities in sorts of a...
L-869298 is a high potent and selective PDE4 inhibitor, acts as a Type 4 cyclic nucleotide phosphodiesterase inhibitor.
Selective phosphodiesterase 4 (PDE4) inhibitor. Antiasthmatic; used in treatment of chronic obstructive pulmonary disease.
CP-671305 is a potent and selective inhibitor of PDE4.
GSK256066 2,2,2-trifluoroacetic acid
GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold...
Ronomilast is type 4 cyclic nucleotide phosphodiesterase inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).
GSK-356278 is a selective Type 4 cyclic nucleotide phosphodiesterase inhibitor. It shows anxiolytic and cognition-enhancing effects and it has the ability to el...
CI-1044, a selective PDE4 inhibitor, inhibits in vitro LPS-induced TNF-alpha release in whole blood from COPD patients better than rolipram and cilomilast and s...
Oglemilast is a potent PDE4 inhibitor and under clinical studies in the treatment of allergen-induced asthma.
Apremilast (CC-10004)is an orally available small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast specifically inhibits PDE4 and inhibits spontaneo...
GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selec...
MK-0359 is a selective and potent oral PDE4 inhibitor with in vivoefficacy in animal models of asthma and cognition.
Zardaverine is a newly developed dual-selective PDE3/4 inhibitor with IC50 values of 0.5 μM and 0.8 μM respectively.
AN3199, a PDE4 inhibitor, was once studied as an anti-inflammatory agent. IC50: 94.5 nM
CP-220629, a Pyrazolopyridin derivative, has been found to be a Type 4 cyclic nucleotide phosphodiesterase inhibitor that was once studied as an anti-inflammato...